Solvotrin irons out global mineral deficiencies

The company has since grown rapidly, doubling from seven to 15 employees in the past year, and will expand to 20 staff members by early next year

19th November, 2017
Pat O'Flynn, chief executive, Solvotrin: ‘We fix products with clever science and the resulting new products avoid the side effects’ John Allen

Irish pharma company Solvotrin Therapeutics is seeking €500,000 in EIIS funding as it ramps up sales of its Active Iron supplements into international markets.

Former Ernst & Young Entrepreneur of the Year finalist Pat O’Flynn, along with pharmaceutical chemist Professor John Gilmer and clinician, entrepreneur and expert adviser to the Irish Medicines Board Dr Mark Ledwidge, established Solvotrin in 2010 as a spin-out from Trinity College Dublin and launched their first product range last year....

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader

Trial

€1

Unlimited Access for 1 Month

Get basic

*New subscribers only

You can cancel any time.

Annual

€200

€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.

Quarterly

€55

€42

90 Day Pass

You can cancel any time.

2 Yearly

€315

€248

Unlimited Access for 2 Years

You can cancel any time.

Team Pass

Get a Business Account for you and your team

Share this post

Related Stories

Construction app helping put site safety first

Paving the way to better roads

Interactive maps point the way to new broadband networks

Awards to highlight how firms have adapted to pandemic